BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

Other languages Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

End-of-day quote Hong Kong S.E. Other stock markets 03:30:00 05/06/2024 am IST			5-day change	1st Jan Change
8.8 ^CNY	-1.90%		-0.79%	-26.54%

06/05	Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	CI
26/04	Biocytogen Pharmaceuticals' Loss Narrows in 2023	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	06/05
Biocytogen Pharmaceuticals' Loss Narrows in 2023	26/04
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	25/03
Biocytogen Pharmaceuticals Co., Ltd Announces Antibody Evaluation and Option Agreement with Gilead Sciences, Inc	19/02
Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics	23/01
Biocytogen Pharmaceuticals Co., Ltd. Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	08/01
Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd Achieve Milestone Progress in Co-Developing A TCR-Mimic Antibody-Based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	27/12
Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	20/12
Biocytogen Pharmaceuticals Co., Ltd. Announce an Antibody Evaluation, Option and License Agreement with Ona Therapeutics	18/12
Biocytogen Pharmaceuticals Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company	12/12
Biocytogen Pharmaceuticals' RenMice Series-Fully Human Antibody and TCR Mouse Models-Showcase Biocytogen's Capabilities to Innovate the Discovery of Biologic Drugs	14/23/14
Myricx Enters into Antibody License Agreement with Biocytogen Pharmaceuticals Co., Ltd	07/23/07
Biocytogen Pharmaceuticals Co., Ltd. Establishes Two Business Divisions to Distinguish Preclinical Models and Services from Antibody Drug R&D	31/23/31
Biocytogen Pharmaceuticals' Loss Narrows in H1; Shares Up 12%	29/23/29
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28
Biocytogen Pharmaceuticals Co., Ltd. Announces Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth	17/23/17
Biocytogen Pharmaceuticals Announces Grand Opening of Waltham, MA Facility	16/23/16
Biocytogen Pharmaceuticals Co., Ltd. Enters into License Agreement with Pheon Therapeutics	05/23/05
Biocytogen Pharmaceuticals Co., Ltd. Opens San Francisco Office to Accelerate Globalization	31/23/31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

Other languages

Filters